Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 7/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | LIPE | Q05469 | 1/20 | 0.40 |
| ▸ | IGF2BP2 | Q9Y6M1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5125009 | 0.88 | TRPV1 (0.59) | TRPV1 | |
| SCHEMBL5118635 | 0.88 | TRPV1 (0.50) | TRPV1IGF2BP2 | |
| SCHEMBL5115060 | 0.85 | TRPV1 (0.47) | TRPV1 | |
| SCHEMBL5120392 | 0.78 | LMNA (0.54) | TRPV1 | |
| SCHEMBL4332016 | 0.77 | TRPV1 (0.64) | TRPV1 | |
| SCHEMBL2734511 | 0.76 | TRPV1 (0.60) | TRPV1 | |
| SCHEMBL2734364 | 0.76 | TRPV1 (0.51) | TRPV1 | |
| SCHEMBL14278386 | 0.76 | NLRP3 (0.49) | TRPV1 | |
| SCHEMBL5981392 | 0.76 | TRPV1 (0.56) | TRPV1 | |
| SCHEMBL5128512 | 0.76 | TRPV1 (0.56) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045546-A1 | Tetradydro-Naphthalene And Urea Derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045546-A1 | Tetradydro-Naphthalene And Urea Derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045546-A1 | Tetradydro-Naphthalene And Urea Derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-02-21 | — | — | US | disclosed |
| EP-1678123-A1 | TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES | Bayer HealthCare AG (DE) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005040100-A1 | TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045546-A1 | Tetradydro-Naphthalene And Urea Derivatives | NMUR1, GPR17, NMUR2 | TRPV1 10/4885GSK3A 3009/4885GSK3B 3169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.